# US 2014/0193448 A1 · Vaccine against multitypes of avian influenza viruses and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193448 A1 - Document ID: US20140193448A1 - Status: Published application - Kind: A1 - Application number: 14/219,000 - Filed: 2014-03-19 - Published: 2014-07-10 - Earliest claimed: 2012-04-18 - Assignees: National Tsing Hua University - Applicants: National Tsing Hua University - Inventors: Suh-Chin Wu; Shih-Chang Lin - Web page: https://patentgrep.com/patent/US20140193448A1 ## CPC - C07K 14/005: from viruses - A61K 39/12: Viral antigens - A61K 39/145: Orthomyxoviridae, e.g. influenza virus - A61K 2039/5256: {expressing foreign proteins} - A61K 2039/5258: {Virus-like particles} - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/55505: {Inorganic adjuvants} - A61K 2039/55516: {Proteins; Peptides} - C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies - C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP] - C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2760/16123: Virus like particles [VLP] - C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2799/022: where the vector is derived from an adenovirus - C12N 2799/026: where the vector is derived from a baculovirus - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule. The present invention still further relates to a method of vaccinating a subject susceptible to avian influenza comprising administrating to the subject an effective amount of the composition as described above. The present invention still further relates to a recombinant hemagglutinin protein consisting of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138, and the combination thereof. ## Claims ### Claim 1 A recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. ### Claim 2 (depends on 1) The recombinant DNA molecule of claim 1, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 4, 10, 33, 35, 37, 39 or 41. ### Claim 3 (depends on 1) The recombinant DNA molecule of claim 1, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 37. ### Claim 4 (depends on 1) The recombinant DNA molecule of claim 1, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 41. ### Claim 5 (depends on 1) A composition comprising the recombinant DNA molecule of claim 1 and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. ### Claim 6 (depends on 5) The composition of claim 5, which has the activity of eliciting an immune response against a plurality of avian influenza virus subtypes in a subject. ### Claim 7 (depends on 1) A kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule of claim 1 and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule. ### Claim 8 (depends on 7) The kit of claim 7, wherein the recombinant hemagglutiinin protein consists of the amino acid sequence of SEQ ID NO: 4, 10, 33, 35, 37, 39 or 41. ### Claim 9 (depends on 5) A method of vaccinating a subject susceptible to avian influenza comprising administrating to the subject an effective amount of the composition of claim 5. ### Claim 10 (depends on 9) The method of claim 9, which comprises a prime-boost administration regimen. ### Claim 11 (depends on 5, 10) The method of claim 10, wherein the prime-boost administration regimen comprises a prime-administration of a composition of claim 5. ### Claim 12 (depends on 5, 10) The method of claim 10, wherein the prime-boost administration regimen comprises a boost administration of a composition of claim 5. ### Claim 13 (depends on 5, 10) The method of claim 10, wherein the prime-boost administration regimen comprises a prime-administration of a composition of claim 5 and a boost administration of a composition comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule. ### Claim 14 (depends on 13) The method of claim 13, wherein the recombinant hemagglutiinin protein consists of the amino acid sequence of SEQ ID NO: 4, 10, 33, 35, 37, 39 or 41. ### Claim 15 (depends on 9) The method of claim 9, which elicits an immune response against multiple avian influenza virus subtypes in the subject. ### Claim 16 A recombinant hemagglutinin protein consisting of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138, and the combination thereof. ### Claim 17 (depends on 16) The recombinant hemagglutinin protein of claim 16, which consists of the amino acid sequence of SEQ ID NO: 4, 10, 33, 35, 37, 39 or 41. ### Claim 18 (depends on 16) The recombinant hemagglutinin protein of claim 16, which consists of the amino acid sequence of SEQ ID NO: 37. ### Claim 19 (depends on 16) The recombinant hemagglutinin protein of claim 16, which consists of the amino acid sequence of SEQ ID NO: 41.